{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:06:41Z","timestamp":1783951601745,"version":"3.55.0"},"reference-count":16,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,5]]},"abstract":"ABSTRACT<\/jats:title>\n \n Eravacycline is a novel broad-spectrum fluorocycline antibiotic being developed for a wide range of serious infections. Eravacycline was efficacious in mouse septicemia models, demonstrating 50% protective dose (PD\n 50<\/jats:sub>\n ) values of \u22641 mg\/kg of body weight once a day (q.d.) against\n Staphylococcus aureus<\/jats:named-content>\n , including tetracycline-resistant isolates of methicillin-resistant\n S. aureus<\/jats:named-content>\n (MRSA), and\n Streptococcus pyogenes<\/jats:named-content>\n . The PD\n 50<\/jats:sub>\n values against\n Escherichia coli<\/jats:named-content>\n isolates were 1.2 to 4.4 mg\/kg q.d. In neutropenic mouse thigh infection models with methicillin-sensitive\n S. aureus<\/jats:named-content>\n (MSSA) and\n S. pyogenes<\/jats:named-content>\n , eravacycline produced 2 log\n 10<\/jats:sub>\n reductions in CFU at single intravenous (i.v.) doses ranging from 0.2 to 9.5 mg\/kg. In a neutropenic mouse lung infection model, eravacycline administered i.v. at 10 mg\/kg twice a day (b.i.d.) reduced the level of tetracycline-resistant MRSA in the lung equivalent to that of linezolid given orally (p.o.) at 30 mg\/kg b.i.d. At i.v. doses of 3 to 12 mg\/kg b.i.d., eravacycline was more efficacious against tetracycline-resistant\n Streptococcus pneumoniae<\/jats:named-content>\n in a neutropenic lung infection model than linezolid p.o. at 30 mg\/kg b.i.d. Eravacycline showed good efficacy at 2 to 10 mg\/kg i.v. b.i.d., producing up to a 4.6 log\n 10<\/jats:sub>\n CFU reduction in kidney bacterial burden in a model challenged with a uropathogenic\n E. coli<\/jats:named-content>\n isolate. Eravacycline was active in multiple murine models of infection against clinically important Gram-positive and Gram-negative pathogens.\n <\/jats:p>","DOI":"10.1128\/aac.04354-14","type":"journal-article","created":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T03:01:46Z","timestamp":1424228506000},"page":"2567-2571","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Eravacycline (TP-434) Is Efficacious in Animal Models of Infection"],"prefix":"10.1128","volume":"59","author":[{"given":"Trudy H.","family":"Grossman","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Vivisource Laboratories, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Slee","sequence":"additional","affiliation":[{"name":"Vivisource Laboratories, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denene","family":"Lofland","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce A.","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Antibiotic resistance threats in the United States, 2013","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/605630"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/533452"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/652237"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06187-11"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-13"},{"key":"e_1_3_2_10_2","volume-title":"Abstr 49th Annu Meet Infect Dis Am Annu Meeting","author":"Horn PT","year":"2011","unstructured":"Horn PT, Sutcliffe JA, Walpole SM, Leighton A. 2011. Pharmacokinetics, safety and tolerability of a novel fluorocycline, TP-434, following multiple dose oral administration with and without food, abstr 603. Abstr 49th Annu Meet Infect Dis Am Annu Meeting, Boston, MA, 20 to 23 October 2011."},{"key":"e_1_3_2_11_2","volume-title":"Abstr 50th Annu Intersci Conf Antimicrob Agents Chemother","author":"Ronn M","year":"2010","unstructured":"Ronn M, Dunwoody N, Sutcliffe J. 2010. Pharmacokinetics of TP-434 in mouse, rat, dog, monkey and chimpanzee, abstr F1-2163. Abstr 50th Annu Intersci Conf Antimicrob Agents Chemother, 12 to 15 September 2010."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201465w"},{"key":"e_1_3_2_13_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_14_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 22nd informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/649554"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/592250"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/592251"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04354-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04354-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:57:45Z","timestamp":1645484265000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04354-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1128\/AAC.04354-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04354-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"2014-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}